Drugs / NIR178
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04237649 | Feb 2020 → Sep 2023 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT04895748 | Nov 2021 → Feb 2026 | clear cell renal carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03549000 | Jul 2018 → Oct 2022 | colorectal cancer, non-small cell lung carcinoma, ovarian cancer, pancreatic ductal adenocarcinoma +3 | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02403193 | Oct 2015 → Oct 2021 | non-small cell lung carcinoma | Palobiofarma SL | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03207867 | Aug 2017 → Feb 2023 | colorectal cancer, diffuse large B-cell lymphoma, head and neck cancer, malignant pancreatic neoplasm +6 | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NIR178 | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Known as | PBF509 | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Known as | Taminadenant | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Action | Inhibit | “Taminadenant (PBF509/NIR178) is an A2AR antagonist able to reactivate the antitumor immune response.” PMID 35254415 ↗ Jun 2022 |
| Route | Oral | “NIR178 was administered orally twice daily (BID) as a capsule” NCT03207867 ↗ |